242 related articles for article (PubMed ID: 32249370)
1. A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience.
Watanabe J; Saito M; Horimoto Y; Nakamoto S
Breast Cancer Res Treat; 2020 May; 181(1):211-220. PubMed ID: 32249370
[TBL] [Abstract][Full Text] [Related]
2. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y
BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862
[TBL] [Abstract][Full Text] [Related]
3. Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer.
Goto W; Kashiwagi S; Takada K; Asano Y; Morisaki T; Shibutani M; Tanaka H; Hirakawa K; Ohira M
Anticancer Res; 2022 Feb; 42(2):939-946. PubMed ID: 35093893
[TBL] [Abstract][Full Text] [Related]
4. Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan.
Takahashi M; Inoue K; Mukai H; Yamanaka T; Egawa C; Miyoshi Y; Sakata Y; Muramoto K; Ikezawa H; Matsuoka T; Tsurutani J
Breast Cancer; 2021 Jul; 28(4):945-955. PubMed ID: 33677779
[TBL] [Abstract][Full Text] [Related]
5. Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study.
Nakamoto S; Watanabe J; Ohtani S; Morita S; Ikeda M
BMC Cancer; 2022 Jan; 22(1):31. PubMed ID: 34980019
[TBL] [Abstract][Full Text] [Related]
6. Dynamic Changes in Absolute Lymphocyte Counts During Eribulin Therapy Are Associated With Survival Benefit.
Nakamoto S; Ikeda M; Kubo S; Yamamoto M; Yamashita T
Anticancer Res; 2021 Jun; 41(6):3109-3119. PubMed ID: 34083304
[TBL] [Abstract][Full Text] [Related]
7. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study.
Miyoshi Y; Yoshimura Y; Saito K; Muramoto K; Sugawara M; Alexis K; Nomoto K; Nakamura S; Saeki T; Watanabe J; Perez-Garcia JM; Cortes J
Breast Cancer; 2020 Jul; 27(4):706-715. PubMed ID: 32133606
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial.
Pérez-García JM; Llombart-Cussac A; G Cortés M; Curigliano G; López-Miranda E; Alonso JL; Bermejo B; Calvo L; Carañana V; de la Cruz Sánchez S; M Vázquez R; Prat A; R Borrego M; Sampayo-Cordero M; Seguí-Palmer MÁ; Soberino J; Malfettone A; Schmid P; Cortés J
Eur J Cancer; 2021 May; 148():382-394. PubMed ID: 33794440
[TBL] [Abstract][Full Text] [Related]
9. Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types.
Morisaki T; Kashiwagi S; Asano Y; Goto W; Takada K; Ishihara S; Shibutani M; Tanaka H; Hirakawa K; Ohira M
World J Surg Oncol; 2021 Nov; 19(1):324. PubMed ID: 34775950
[TBL] [Abstract][Full Text] [Related]
10. C-Reactive Protein and Absolute Lymphocyte Count Can Predict Overall Survival of Patients Treated With Eribulin.
Sata A; Fukui R; Miyagawa Y; Bun A; Ozawa H; Fujimoto Y; Higuchi T; Imamura M; Miyoshi Y
Anticancer Res; 2020 Jul; 40(7):4147-4156. PubMed ID: 32620664
[TBL] [Abstract][Full Text] [Related]
11. Validation of Systemic and Local Tumour Immune Response to Eribulin Chemotherapy in the Treatment of Breast Cancer.
Kashiwagi S; Asano Y; Goto W; Takada K; Morisaki T; Kouhashi R; Yabumoto A; Tanaka S; Takashima T; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2020 Jun; 40(6):3345-3354. PubMed ID: 32487630
[TBL] [Abstract][Full Text] [Related]
12. Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study.
Nakamoto S; Watanabe J; Ohtani S; Morita S; Ikeda M
Sci Rep; 2021 Nov; 11(1):21454. PubMed ID: 34728668
[TBL] [Abstract][Full Text] [Related]
13. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.
Kawaguchi H; Masuda N; Nakayama T; Aogi K; Anan K; Ito Y; Ohtani S; Sato N; Saji S; Takano T; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita H; Yamashita T; Yamamoto Y; Yotsumoto D; Toi M; Ohno S
Breast Cancer; 2020 May; 27(3):389-398. PubMed ID: 31811519
[TBL] [Abstract][Full Text] [Related]
15. An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer.
Takashima T; Nishimura S; Kawajiri H; Mizuyama Y; Nishimori T; Yamagata S; Tokunaga S; Tezuka K; Tei S; Sunami T; Ikeda K; Ogawa Y; Kashiwagi S; Noda S; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M
Anticancer Res; 2021 Oct; 41(10):5007-5014. PubMed ID: 34593449
[TBL] [Abstract][Full Text] [Related]
16. Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
Iwasa T; Tsurutani J; Watanabe S; Kato R; Mizuno Y; Kojima Y; Takashima T; Matsunami N; Morimoto T; Yamamura J; Ohtani S; Tanabe Y; Yoshinami T; Takano T; Komoike Y; Nakagawa K
BMC Cancer; 2019 Oct; 19(1):962. PubMed ID: 31619197
[TBL] [Abstract][Full Text] [Related]
17. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
[TBL] [Abstract][Full Text] [Related]
18. Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.
Inoue K; Ninomiya J; Saito T; Okubo K; Nakakuma T; Yamada H; Kimizuka K; Higuchi T;
Invest New Drugs; 2019 Jun; 37(3):538-547. PubMed ID: 30848403
[TBL] [Abstract][Full Text] [Related]
19. Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin.
Su MX; Lin HW; Nguyen HTH; Lin TC; Chen CJ; Wang HC; Wu CT; Wu YC; He GY; Liu LC; Huang CH
BMC Cancer; 2024 Feb; 24(1):195. PubMed ID: 38347468
[TBL] [Abstract][Full Text] [Related]
20. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]